GlassScriptPhysician profile
Juan D Posada
NPI 1437154739
$11,356.61
in general payments reported to CMS, 2019-2025
30 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,498 · 2020: $493 · 2021: $1,941 · 2022: $2,492 · 2023: $978 · 2024: $572 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,095.55 | 2019-2025 | Gallant, Aveir, Jot Dx |
| Biotronik INC. | $1,904.77 | 2019-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Biomonitor |
| Medtronic, INC. | $1,441.47 | 2021-2024 | Cobalt Dr Mri Surescan, Claria Mri Quad Crt-D Surescan, Azure Xt Dr Mri Surescan |
| Cvrx, INC. | $794.12 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $713.99 | 2019-2023 | Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $686.49 | 2019-2025 | Jardiance |
| Abiomed | $609.02 | 2019-2025 | |
| Amgen INC. | $394.46 | 2019-2024 | Repatha |
| Esperion Therapeutics, INC. | $376.29 | 2021-2022 | |
| Shockwave Medical, INC | $286.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $268.36 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $243.03 | 2019-2024 | |
| Pfizer INC. | $205.80 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $174.01 | 2020-2025 | Lokelma |
| Impulse Dynamics (USA) INC. | $167.58 | 2023 | Optimizer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $162.33 | 2020 | |
| Merck Sharp & Dohme LLC | $142.07 | 2021-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $138.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $135.14 | 2025 | Camzyos |
| Cardiovascular Systems INC. | $101.76 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.62 | 2019 | |
| Lemaitre Vascular, INC. | $69.87 | 2019 | |
| Amarin Pharma, INC. | $44.52 | 2019-2021 | |
| Novo Nordisk INC | $39.75 | 2019-2025 | Wegovy |
| Irhythm Technologies, INC. | $20.91 | 2019 | |
| United Therapeutics Corporation | $19.16 | 2019 | |
| Bridgebio Pharma, INC. | $17.42 | 2025 | Attruby |
| Gilead Sciences, INC. | $14.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.06 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Posada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.